
    
      1.1 To determine, in a historical comparison with TT II (Thalidomide arm), whether two cycles
      of VDTPACE induction (instead of four induction cycles in TT II) followed by more timely MEL
      200-based transplant with DEX + THAL between transplants can:

      1.1.1 Increase the CR frequency from 50% to 60% at 18 months from initiation of therapy;

      1.1.2 Increase > n-CR rate pre-transplant #1 from 20% to 40%;

      1.1.3 Raise 2-year EFS rates from 55% to 75% in patients with CA and from 80% to 95%, in
      patients without CA.
    
  